title: One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
abstract: A double blind placebo controlled trial was performed to evaluate the effects of the aldose reductase inhibitor, ponalrestat, on symptomatic diabetic neuropathy. After a 4-week placebo run-in phase, 60 patients were 2:1 randomized to receive either 600 mg ponalrestat or placebo once daily over 12 months. Forty-six patients, 30 of whom were treated with ponalrestat and 16 with placebo, completed the study. Motor and sensory nerve conduction, thermal and vibration sensation thresholds, heart rate variation at rest, E/I ratio, pupillary dilation velocity and pupillary reflex latency were determined at baseline and after 6 and 12 months. Neuropathic symptom scores were assessed every 3 months. Among the fifteen nerve function parameters studied, only trends in favour of ponalrestat were noted for heart rate variation and E/I ratio after 6 months (P = 0.06), but no significant differences between the groups could be demonstrated during the study. No adverse reactions were observed. It is concluded that one-year treatment with ponalrestat has no beneficial effects on symptoms or electrophysiological parameters in diabetic neuropathy.
authors.affiliation: Diabetes Research Institute, Heinrich-Heine-University, Düsseldorf, F.R.G.
authors.forename: D
authors.initials: D
authors.lastname: Ziegler
authors.forename: P
authors.initials: P
authors.lastname: Mayer
authors.forename: W
authors.initials: W
authors.lastname: Rathmann
authors.forename: F A
authors.initials: FA
authors.lastname: Gries
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008475:Median Nerve / Q000503:physiopathology; D008875:Middle Aged; D009460:Neurologic Examination; D010543:Peroneal Nerve / Q000503:physiopathology; D010793:Phthalazines / Q000009:adverse effects / Q000627:therapeutic use*; D012025:Reflex, Pupillary / Q000187:drug effects; D013497:Sural Nerve / Q000503:physiopathology; D014732:Vibration
chemical_list: D010793:Phthalazines; C042829:ponalrestat; D000449:Aldehyde Reductase